Shares of Swiss clinical-stage pharmaceutical company NLS Pharmaceutics AG (NLSP) are climbing more than 4% Thursday morning.
NLS today said, the FDA has accepted its investigational new drug application (IND) for Quilience, the Company's lead drug candidate, for the treatment of narcolepsy.
The company plans to start Phase 2a study of Quilience in August 2021.
NLSP is at $3.13 currently. It has traded in the range of $2.06- $7.35 in the last one year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.